JPWO2022212700A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022212700A5
JPWO2022212700A5 JP2023560496A JP2023560496A JPWO2022212700A5 JP WO2022212700 A5 JPWO2022212700 A5 JP WO2022212700A5 JP 2023560496 A JP2023560496 A JP 2023560496A JP 2023560496 A JP2023560496 A JP 2023560496A JP WO2022212700 A5 JPWO2022212700 A5 JP WO2022212700A5
Authority
JP
Japan
Prior art keywords
lys
1peg2
substituted
pharma
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023560496A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513391A5 (https=
JP7849383B2 (ja
JP2024513391A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/022817 external-priority patent/WO2022212700A2/en
Publication of JP2024513391A publication Critical patent/JP2024513391A/ja
Publication of JP2024513391A5 publication Critical patent/JP2024513391A5/ja
Publication of JPWO2022212700A5 publication Critical patent/JPWO2022212700A5/ja
Application granted granted Critical
Publication of JP7849383B2 publication Critical patent/JP7849383B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023560496A 2021-04-01 2022-03-31 コンジュゲートされたヘプシジン模倣物 Active JP7849383B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163169545P 2021-04-01 2021-04-01
US63/169,545 2021-04-01
US202263325328P 2022-03-30 2022-03-30
US63/325,328 2022-03-30
PCT/US2022/022817 WO2022212700A2 (en) 2021-04-01 2022-03-31 Conjugated hepcidin mimetics

Publications (4)

Publication Number Publication Date
JP2024513391A JP2024513391A (ja) 2024-03-25
JP2024513391A5 JP2024513391A5 (https=) 2025-03-06
JPWO2022212700A5 true JPWO2022212700A5 (https=) 2025-03-06
JP7849383B2 JP7849383B2 (ja) 2026-04-21

Family

ID=83459967

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560496A Active JP7849383B2 (ja) 2021-04-01 2022-03-31 コンジュゲートされたヘプシジン模倣物

Country Status (7)

Country Link
US (1) US20240209053A1 (https=)
EP (1) EP4314014A4 (https=)
JP (1) JP7849383B2 (https=)
AU (1) AU2022249097A1 (https=)
CA (1) CA3214153A1 (https=)
TW (1) TW202304952A (https=)
WO (1) WO2022212700A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2968443T3 (da) 2013-03-15 2021-12-06 Protagonist Therapeutics Inc Hepcidinanaloger og anvendelser deraf
PT3143037T (pt) 2014-05-16 2021-09-24 Protagonist Therapeutics Inc Antagonistas peptídicos tioéter de integrina alfa4beta7
US9624268B2 (en) 2014-07-17 2017-04-18 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
EP3749345A4 (en) 2018-02-08 2022-04-06 Protagonist Therapeutics, Inc. CONJUGATED HEPCIDIN MIMETICS
AU2021209086A1 (en) 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2021383828A1 (en) 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
WO2023288019A2 (en) 2021-07-14 2023-01-19 Janssen Biotech, Inc. Lipidated peptide inhibitors of interleukin-23 receptor
EP4472995A4 (en) * 2022-02-02 2025-11-19 Protagonist Therapeutics Inc Conjugated hepcidin mimetics

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US20040152868A1 (en) * 2001-03-30 2004-08-05 Larsen Bjarne Due Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease
WO2007093013A1 (en) 2006-02-17 2007-08-23 Monash University Methods for the synthesis of dicarba bridges in organic compounds
CN102245626A (zh) * 2008-12-05 2011-11-16 加利福尼亚大学董事会 微型铁调素肽及其使用方法
US9624268B2 (en) * 2014-07-17 2017-04-18 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US20190002503A1 (en) * 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
EP3749345A4 (en) * 2018-02-08 2022-04-06 Protagonist Therapeutics, Inc. CONJUGATED HEPCIDIN MIMETICS

Similar Documents

Publication Publication Date Title
US11753443B2 (en) Conjugated hepcidin mimetics
JPWO2022026629A5 (https=)
JP2026012422A (ja) コンジュゲート型ヘプシジン模倣体
JP7849383B2 (ja) コンジュゲートされたヘプシジン模倣物
JP2012530145A5 (https=)
RU2013154047A (ru) Пептидные лекарственные препараты с повышенной эффективностью против инсулинорезистентности
JP2009532384A5 (https=)
JPWO2022026631A5 (https=)
WO2017117411A1 (en) Analogues of hepcidin mimetics with improved in vivo half lives
AU2022249095A1 (en) Conjugated hepcidin mimetics
WO2022212698A1 (en) Conjugated hepcidin mimetics
JP2024520861A (ja) 遺伝性ヘモクロマトーシスの治療のためのヘプシジン模倣体
JP2009532385A5 (https=)
CN109106942B (zh) 一种可通过血脑屏障的多肽在制备药物中的应用
JPWO2022212700A5 (https=)
JPWO2022212696A5 (https=)
JPWO2020120984A5 (https=)
CN109265558B (zh) 改进型齐考诺肽在制备药物中的应用
AR125266A1 (es) Miméticos de hepcidina conjugados
EA053112B1 (ru) Конъюгированные миметики гепсидина
AR125265A1 (es) Miméticos de hepcidina conjugados
CN117813313A (zh) 结合型铁调素模拟物
CN117480176A (zh) 用于治疗遗传性血色病的铁调素模拟物
CN117730089A (zh) 结合型铁调素模拟物
NZ822560B2 (en) Novel triple glp-1/gip/glucagon receptor agonist and a pharmaceutical composition for preventing or treating obesity comprising the same